GlassScriptPhysician profile
Duo Xu
NPI 1508645771
$3,441.42
in general payments reported to CMS, 2019-2025
28 companies · $1,240 in 2025
The $1,240 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $70.74 · 2024: $2,130 · 2025: $1,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,321 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,320.89 |
| Education | $120.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $529.79 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $488.02 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $290.30 | 2024-2025 | Xifaxan, Relistor, Plenvu |
| Pfizer INC. | $284.72 | 2023-2025 | |
| Celgene Corporation | $269.22 | 2023-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $198.23 | 2024 | |
| Madrigal Pharmaceuticals | $182.87 | 2025 | Rezdiffra |
| Ardelyx, INC. | $168.88 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $143.39 | 2024-2025 | Iqirvo, Bylvay |
| Takeda Pharmaceuticals U.S.A., INC. | $124.22 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Merck Sharp & Dohme LLC | $118.70 | 2024 | Dificid |
| Genzyme Corporation | $98.34 | 2024-2025 | |
| Gilead Sciences, INC. | $80.70 | 2025 | |
| Qol Medical, LLC | $71.31 | 2025 | Sucraid |
| Celltrion USA INC. | $57.49 | 2024-2025 | Zymfentra, Vegzelma |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $37.76 | 2024 | |
| Janssen Scientific Affairs, LLC | $35.45 | 2024 | Tremfya |
| Phathom Pharmaceuticals, INC. | $30.39 | 2025 | Voquezna |
| Exact Sciences Corporation | $29.31 | 2023 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $28.21 | 2024 | Suflave |
| Amgen INC. | $26.10 | 2024 | |
| Sandoz INC. | $25.82 | 2024 | |
| Lilly USA, LLC | $25.70 | 2024 | Omvoh |
| Vivus LLC | $23.14 | 2024 | Qsymia |
| Pharming Healthcare, INC. | $19.82 | 2024 | Ruconest |
| Aimmune Therapeutics, INC. | $18.62 | 2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $18.21 | 2025 | Dupixent |
| Evoke Pharma, INC. | $16.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duo Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.